Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chronic lower respiratory diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    88 result(s) found for: Chronic lower respiratory diseases. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2016-000734-21 Sponsor Protocol Number: 2014RC07 Start Date*: 2016-09-07
    Sponsor Name:University of Dundee & NHS Tayside
    Full Title: Investigating the mechanism of inhaled corticosteroids associated pneumonia by longitudinal characterisation of the airway microbiome in patients with severe COPD
    Medical condition: Chronic Obstructive Pulmonary Diseae
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005637-11 Sponsor Protocol Number: BV-2007/06 Start Date*: 2008-08-04
    Sponsor Name:OM Pharma SA
    Full Title: Efficacy of Broncho-Vaxom in elderly patients with chronic bronchitis; a double-blind, randomised, placebo-controlled study
    Medical condition: Chronic bronchitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10008841 Chronic bronchitis LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-001818-38 Sponsor Protocol Number: EFC16750 Start Date*: 2021-03-02
    Sponsor Name:Sanofi-Aventis Recherche & Developpement
    Full Title: Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with mode...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    26.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001940-71 Sponsor Protocol Number: BV2013/5 Start Date*: 2013-12-10
    Sponsor Name:OM Pharma SA
    Full Title: A Randomized, Placebo Controlled, Double Blinded, Mechanistic trial to investigate the effects of Broncho-Vaxom (OM-85 BV) on the innate immune system in patients with COPD
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020440-35 Sponsor Protocol Number: D589BC00004 Start Date*: 2011-09-16
    Sponsor Name:Imperial College London
    Full Title: GR activity in induced sputum macrophages, and a change in inflammatory biomarkers 2-hours after a single dose of either Symbicort®/Budesonide/Formoterol or placebo in Chronic Obstructive Pulmonary...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-002474-36 Sponsor Protocol Number: GS-US-218-0108 Start Date*: 2014-11-24
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT...
    Medical condition: Respiratory Syncytial Virus (RSV) Infection of the upper respiratory tract.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10039247 RSV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-004375-40 Sponsor Protocol Number: NGAM-12 Start Date*: 2020-07-09
    Sponsor Name:Octapharma Pharmazeutika Produktionsges.m.b.H.
    Full Title: Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia (“...
    Medical condition: Primary infection prophylaxis in patients with chronic lymphocytic leukemia (CLL) and secondary hypogammaglobulinemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001981-36 Sponsor Protocol Number: 219238 Start Date*: 2022-11-15
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A Phase 3, observer-blind, randomized, placebo controlled study to evaluate the non inferiority of the immune response and safety of the RSVPreF3 OA investigational vaccine in adults 50-59 years of...
    Medical condition: Respiratory syncytial virus infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10035732 Pneumonia respiratory syncytial viral PT
    21.1 10021881 - Infections and infestations 10038718 Respiratory syncytial virus bronchiolitis PT
    21.1 10021881 - Infections and infestations 10069811 Respiratory syncytial virus bronchitis PT
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    21.1 10021881 - Infections and infestations 10035692 Pneumonia due to respiratory syncytial virus LLT
    21.1 10021881 - Infections and infestations 10067384 Respiratory syncytial virus pneumonitis LLT
    21.1 10021881 - Infections and infestations 10052200 Respiratory syncytial virus infection NOS LLT
    21.1 10021881 - Infections and infestations 10066741 Respiratory syncytial virus infection recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) NL (Ongoing) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002806-30 Sponsor Protocol Number: PUL-042-402 Start Date*: 2018-12-14
    Sponsor Name:Pulmotect, Inc.
    Full Title: A Phase 2, Single-Center, Double-Blind, Placebo-Controlled, Study of PUL-042 Inhalation Solution in Rhinovirus-induced Symptoms in Current Smokers with Gold Stage 0 Chronic Obstructive Pulmonary Di...
    Medical condition: GOLD (Global Initiative for Chronic Obstructive Lung Disease) stage 0 Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2010-023681-45 Sponsor Protocol Number: EndotoxinexpoIII Start Date*: 2012-05-04
    Sponsor Name:Verksamhetsområde Geriatrik, Lungmedicin och Allergologi vid Sahlgrenska Universitetssjukhuset
    Full Title: Endotoxin-induced immune response in the lower respiratory tract in smokers with and without chronic bronchitis (CB) and / or chronic obstructive pulmonary disease (COPD)
    Medical condition: Airway inflammation in smokers with and without COPD and / or CB
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001667-24 Sponsor Protocol Number: PC_RSV_004 Start Date*: 2018-08-21
    Sponsor Name:Pulmocide Ltd
    Full Title: A double blind, placebo-controlled study to assess the anti-viral effect, safety and tolerability of inhaled PC786 for the treatment of acute respiratory syncytial virus (RSV) infection in adult he...
    Medical condition: Respiratory Syncytial Virus
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002199-15 Sponsor Protocol Number: 12/0036 Start Date*: 2013-09-26
    Sponsor Name:Imperial College London
    Full Title: A Phase III double-blind, randomised, placebo controlled trial of long term therapy on Exacerbation Rate in patients with stable COPD using Doxycycline
    Medical condition: COPD Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10010952 COPD LLT
    16.1 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001362-18 Sponsor Protocol Number: GS-US-205-0160 Start Date*: 2012-03-19
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: Open-Label Phase 3 Trial to Evaluate the Safety of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Children with Cystic Fibrosis (CF) and Chron...
    Medical condition: cystic fibrosis and chronic infection of lower respiratory tract with Pseudomonas aeruginosa
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10068288 Cystic fibrosis pulmonary exacerbation LLT
    14.1 10021881 - Infections and infestations 10070608 Infective pulmonary exacerbation of cystic fibrosis PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) FR (Ongoing) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-001909-77 Sponsor Protocol Number: VAC18193RSV3006 Start Date*: 2021-09-22
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Immunogenicity of an Ad26.RSV.preF-based Vaccine in Adults Aged 18 to 59Years, Including Those at High-risk f...
    Medical condition: Prevention of Lower Respiratory Tract Disease Caused by The respiratory syncytial virus (RSV)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10039247 RSV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-003399-58 Sponsor Protocol Number: COPTRIN1 Start Date*: 2017-01-14
    Sponsor Name:COP:TRIN Region Hovedstaden (Gentofte hospital)
    Full Title: Target-ABC (Targeted AntiBiotics for Chronic pulmonary disease): Can targeted antibiotic therapy improve the prognosis of Pseudomonas aeruginosa infected patients with chronic pulmonary obstructiv...
    Medical condition: Respiratory tract infection Bacterial infection with Pseudomonas aeruginosa Chronic obstructive pulmonary disease (COPD) Non-cystic fibrosis bronchiectasis Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10021860 Infection Pseudomonas aeruginosa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005075-38 Sponsor Protocol Number: D5290C00006 Start Date*: 2023-10-10
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Nirsevimab, a Monoclonal Antibody With Extended Half-life Against Respiratory Syncytial Virus, i...
    Medical condition: Medically attended Respiratory Syncytial Viral (RSV) Lower respiratory tract infection(LRTI)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10066742 Respiratory syncytial virus infection prophylaxis LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2014-002137-58 Sponsor Protocol Number: GS-US-218-1227 Start Date*: 2014-09-29
    Sponsor Name:Gilead Sciences Inc
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults with Respirato...
    Medical condition: Respiratory Syncytial Virus (RSV) Infection
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10039247 RSV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2025-000021-13 Sponsor Protocol Number: D5290C00009 Start Date*: 2025-04-24
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III Single-Arm Open-Label Study to Evaluate the Safety PK ADA and Anti RSV nAb Following Administration of 2 Doses of Nirsevimab Given 5 to 6 Months Apart in Infants With CHD, CLD, Immunoco...
    Medical condition: Medically attended Respiratory Syncytial Viral (RSV) Lower respiratory tract infection(LRTI)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10066742 Respiratory syncytial virus infection prophylaxis LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2009-015713-51 Sponsor Protocol Number: 205.452 Start Date*: 2010-06-09
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG, Medical Affairs Germany
    Full Title: A randomized, active-controlled, double-blind, double-dummy, parallel group design, multi-center trial to compare the efficacy and safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution delivered...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) FI (Completed) LV (Completed) HU (Completed) NO (Completed) LT (Completed) SK (Completed) SE (Completed) ES (Completed) NL (Completed) DK (Completed) PT (Completed) GR (Completed) AT (Completed) IT (Completed) IE (Completed) BG (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002287-16 Sponsor Protocol Number: GS-US-218-1797 Start Date*: 2015-10-15
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2b, Randomized, Controlled Trial Evaluating GS-5806 in Lung Transplant (LT) Recipients with Respiratory Syncytial Virus (RSV) Infection
    Medical condition: Respiratory Syncytial Virus (RSV) Infection
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10039247 RSV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) AT (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 17:54:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA